Gregory Bell, M.D.

Gregory Bell, M.D. is the Chief Medical Officer of QuantX Biosciences. Prior to joining QuantX, Dr. Bell was the Chief Medical Officer at Attralus, Inc, a company focused on developing novel immunotherapies for the treatment (and diagnosis) of various forms of systemic amyloidosis. Dr. Bell was previously Senior Vice President, Development and Chief Medical Officer at KAI Pharmaceuticals, where he discovered peptide agonists of the calcium sensing receptor and led the global development of Parsabiv® until Amgen acquired KAI in 2012. In 2013 Dr. Bell joined Genentech as Vice President, Safety Risk Management of the Immunology, Infectious Disease and Ophthalmology portfolio. Dr. Bell started his drug development career with Merck & Co, where he contributed to several products that received regulatory approval including Vioxx®, Etoricoxib® and Cancidas®.

Dr. Bell earned his medical degree from Cornell University Medical College and completed his training in Internal Medicine and Rheumatology at Brown University and the University of California, San Francisco (UCSF), respectively. Dr. Bell is a member of the American College of Rheumatology (ACR) and has served in leadership roles in the ACR.